TOKYO, Oct 30- Japan's Fujifilm Holdings Corp said it was difficult to estimate the profitability of its influenza drug Avigan, which has been earmarked to fight Ebola, given the uncertainty over the spread of virus, a company executive said on Thursday. France and Guinea plan to conduct clinical trials of Avigan 200 mg tablets, made by Fujifilm group company...» Read More
Faced with more service members returning without limbs from Iraq and Afghanistan, scientists, the government and private-sector companies are using new materials, tools and techniques to create sophisticated prostheses for amputees.
There is a great chance that Sirius XM Radio’s stock will hit $1.65 within the next several sessions — in other words, this is bound to get worse before it gets better.
Here’s a look at several under-$10 stocks that look poised to potentially trade higher from current levels.
Many jobs that let reserved types work in solitude offer poor salaries and unchallenging work. But there are other careers that are stimulating, well-paying and require little human contact.
We pulled together a list of Cramer's favorite dividend plays. Read on and pick one or two for your portfolio. They could offer just the kind of defense that you need.
There are too many options but no one solution to the energy problem. Our needs are many. The current alternative energies — solar, wind, biofuels, nuclear and geothermal — all have limitations, but they're worth it until something better comes along.
Sanofi-Aventis has been quick to move before its patents on bestselling products expired, said CEO Chris Viehbacher.
Mad Money's Cramer runs through a ten-point checklist to see if Celgene is in a position to deliver growth to investors.
Cramer's analysis on Allergan shows that it's a high-quality stock that can be bought into weakness.
Investors are suddenly hot for biotechnology, and that helps Celgene, CEO Robert Hugin told CNBC Thursday.
The S&P Biotech Index is up more than 10 percent and Celgene is one of its biggest gainers. Robert Hugin, Celgene chairman & CEO, discusses what's driving the company's growth, including its recent acquisition of Avila Therapeutics.
CNBC's Seema Mody has the details on Regeneron Pharmaceuticals and Amgen releasing data on injectable drugs.
The Brookings Institution analyzed the financial data of the world’s largest metropolitan areas and uncovered some interesting findings. Check out which cities were the most productive.
Speculation has its place, but Cramer's researcher thinks there is lots of opportunity to profit from established companies, too.
Six out of the 10 patients treated for hepatitis C with a combination of Gilead Science’s experimental drug GS-7977 relapsed, the company disclosed Friday. “This is just par for the course. There’s a reason people do trials on their drugs. You don't know what the answer is until you get the data,” said ISI analyst Mark Schoenebaum, who has a “buy” rating on Gilead.
Investors are riding a wave of unprecedented optimism following what seems like an avalanche of biotech deals, early drug approvals, and positive clinical news that has kicked off the year. TheStreet.com reports.
Find out why he’s bullish on this biotech name.
Mad Money's Cramer, takes a look at Biogen Idec's medical breakthrough drugs and its near-term catalysts for growth this year.
Fast Money trader Karen Finerman explains what's behind Roche's tender offer for Illumina; and the best way to play the biotech takeout trend.
Len Schleifer, Regeneron Pharmaceuticals CEO, discusses smart biotech investing and growth prospects in the company's pipeline, with Mad Money's Jim Cramer.